| Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making E Bakker, K Plueschke, CJ Jonker, X Kurz, V Starokozhko, PGM Mol Clinical Pharmacology & Therapeutics 113 (1), 135-151, 2023 | 43 | 2023 |
| Biomarker qualification at the European Medicines Agency: a review of biomarker qualification procedures from 2008 to 2020 E Bakker, NM Hendrikse, F Ehmann, DS Van der Meer, J Llinares Garcia, ... Clinical Pharmacology & Therapeutics 112 (1), 69-80, 2022 | 24 | 2022 |
| Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe CJ Jonker, E Bakker, X Kurz, K Plueschke Frontiers in Pharmacology 13, 924648, 2022 | 17 | 2022 |
| Handling of New Drug Safety Information in the Dutch Hospital Setting: A Mixed Methods Approach E de Vries, E Bakker, RDC Francisca, S Croonen, P Denig, PGM Mol Drug safety 45 (4), 369-378, 2022 | 4 | 2022 |
| Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting E Bakker, PGM Mol, J Nabais, T Vetter, M Kretzler, JJ Nolan, G Mayer, ... Frontiers in Pharmacology 12, 662642, 2021 | 2 | 2021 |
| Factors Influencing Preferences and Responses Towards Drug Safety Communications: A Conjoint Experiment Among Hospital-Based Healthcare Professionals in the Netherlands E de Vries, E Bakker, TBM Monster, P Denig, PGM Mol Drug Safety 45 (11), 1369-1380, 2022 | 1 | 2022 |
